VERICEL CORPORATION Revenue from Contract with Customer, Excluding Assessed Tax
VERICEL CORPORATION (VCEL) reported Revenue from Contract with Customer, Excluding Assessed Tax of $77.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $77.46M, a 22.48% increase year-over-year.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $68.42M, a 30.09% increase year-over-year.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $92.92M, a 23.27% increase year-over-year.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $67.50M, a 16.58% increase year-over-year.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $276.26M, a 16.45% increase from fiscal 2024.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $237.22M, a 20.10% increase from fiscal 2023.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $197.52M, a 20.66% increase from fiscal 2022.
- VERICEL CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $163.70M, a 6.94% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $77.46M 10-Q · filed 2026-07-30 | $145.88M 10-Q · filed 2026-07-30 | $238.80M derived: sum of 3 quarters · filed 2026-07-30 | $306.30M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $68.42M 10-Q · filed 2026-05-07 | $161.34M derived: sum of 2 quarters · filed 2026-05-07 | $228.85M derived: sum of 3 quarters · filed 2026-05-07 | $292.09M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $92.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $160.42M derived: sum of 2 quarters · filed 2026-02-26 | $223.66M derived: sum of 3 quarters · filed 2026-07-30 | $276.26M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $67.50M 10-Q · filed 2025-11-06 | $130.74M derived: sum of 2 quarters · filed 2026-07-30 | $183.34M 10-Q · filed 2025-11-06 | $258.72M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $63.24M 10-Q · filed 2026-07-30 | $115.84M 10-Q · filed 2026-07-30 | $191.21M derived: sum of 3 quarters · filed 2026-07-30 | $249.12M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $52.60M 10-Q · filed 2026-05-07 | $127.97M derived: sum of 2 quarters · filed 2026-05-07 | $185.88M derived: sum of 3 quarters · filed 2026-05-07 | $238.54M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $75.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $133.28M derived: sum of 2 quarters · filed 2026-02-26 | $185.94M derived: sum of 3 quarters · filed 2026-02-26 | $237.22M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $57.91M 10-Q · filed 2025-11-06 | $110.57M derived: sum of 2 quarters · filed 2025-11-06 | $161.85M 10-Q · filed 2025-11-06 | $226.84M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $52.66M 10-Q · filed 2025-07-31 | $103.94M 10-Q · filed 2025-07-31 | $168.94M derived: sum of 3 quarters · filed 2026-02-26 | $214.52M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $51.28M 10-Q · filed 2025-05-08 | $116.28M derived: sum of 2 quarters · filed 2026-02-26 | $161.86M derived: sum of 3 quarters · filed 2026-02-26 | $207.78M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $65.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $110.58M derived: sum of 2 quarters · filed 2026-02-26 | $156.50M derived: sum of 3 quarters · filed 2026-02-26 | $197.52M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $45.58M 10-Q · filed 2024-11-07 | $91.50M derived: sum of 2 quarters · filed 2024-11-07 | $132.52M 10-Q · filed 2024-11-07 | $185.21M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $45.92M 10-Q · filed 2024-08-01 | $86.94M 10-Q · filed 2024-08-01 | $139.63M derived: sum of 3 quarters · filed 2025-02-27 | $177.96M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $41.02M 10-Q · filed 2024-05-08 | $93.71M derived: sum of 2 quarters · filed 2025-02-27 | $132.04M derived: sum of 3 quarters · filed 2025-02-27 | $168.86M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $52.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $91.02M derived: sum of 2 quarters · filed 2025-02-27 | $127.85M derived: sum of 3 quarters · filed 2025-02-27 | $163.70M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $38.33M 10-Q · filed 2023-11-08 | $75.15M derived: sum of 2 quarters · filed 2023-11-08 | $111.00M 10-Q · filed 2023-11-08 | $158.05M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | $36.83M 10-Q · filed 2023-08-02 | $72.68M 10-Q · filed 2023-08-02 | $119.73M derived: sum of 3 quarters · filed 2024-02-29 | $153.45M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | $35.85M 10-Q · filed 2023-05-10 | $82.90M derived: sum of 2 quarters · filed 2024-02-29 | $116.62M derived: sum of 3 quarters · filed 2024-02-29 | $155.30M derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | $47.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $80.77M derived: sum of 2 quarters · filed 2024-02-29 | $119.45M derived: sum of 3 quarters · filed 2024-02-29 | $153.07M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $33.72M 10-Q · filed 2022-11-09 | $72.40M derived: sum of 2 quarters · filed 2022-11-09 | $106.03M 10-Q · filed 2022-11-09 | $150.28M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $38.68M 10-Q · filed 2022-08-03 | $72.31M 10-Q · filed 2022-08-03 | $116.56M derived: sum of 3 quarters · filed 2023-02-23 | $147.58M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $33.63M 10-Q · filed 2022-05-04 | $77.88M derived: sum of 2 quarters · filed 2023-02-23 | $108.90M derived: sum of 3 quarters · filed 2023-02-23 | $128.92M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $44.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $75.28M derived: sum of 2 quarters · filed 2023-02-23 | $95.29M derived: sum of 3 quarters · filed 2023-02-23 | $121.97M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $31.02M 10-Q · filed 2021-11-09 | $51.03M derived: sum of 2 quarters · filed 2021-11-09 | $77.71M 10-Q · filed 2021-11-09 | $117.10M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $20.01M 10-Q · filed 2021-08-04 | $46.69M 10-Q · filed 2021-08-04 | $86.08M derived: sum of 3 quarters · filed 2021-08-04 | $116.58M derived: sum of 4 quarters · filed 2021-08-04 | |
| 2020-03-31 | $26.68M 10-Q · filed 2021-05-05 | $66.07M derived: sum of 2 quarters · filed 2021-05-05 | $96.57M derived: sum of 3 quarters · filed 2021-05-05 | $122.72M derived: sum of 4 quarters · filed 2021-05-05 | |
| 2019-12-31 | $39.39M 10-K · filed 2020-02-25 | $69.89M derived: sum of 2 quarters · filed 2020-11-05 | $96.04M derived: sum of 3 quarters · filed 2020-11-05 | $117.85M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $30.50M 10-Q · filed 2020-11-05 | $56.65M derived: sum of 2 quarters · filed 2020-11-05 | $78.46M 10-Q · filed 2020-11-05 | $109.80M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $26.15M 10-Q · filed 2020-08-05 | $47.96M 10-Q · filed 2020-08-05 | $79.30M derived: sum of 3 quarters · filed 2020-08-05 | $101.78M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | $21.81M 10-Q · filed 2020-05-11 | $22.00K 10-Q · filed 2019-05-07 | $53.15M derived: sum of 2 quarters · filed 2020-05-11 | $75.63M derived: sum of 3 quarters · filed 2020-05-11 | $94.64M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $31.34M 10-K · filed 2020-02-25 | $53.82M derived: sum of 2 quarters · filed 2020-02-25 | $72.83M derived: sum of 3 quarters · filed 2020-02-25 | $90.86M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $22.48M 10-K · filed 2020-02-25 | $41.49M derived: sum of 2 quarters · filed 2020-02-25 | $59.52M 10-Q · filed 2019-11-05 | $81.71M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-06-30 | $19.01M 10-K · filed 2020-02-25 | $37.04M 10-Q · filed 2019-08-06 | $59.22M derived: sum of 3 quarters · filed 2020-02-25 | $73.48M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-03-31 | $18.03M 10-K · filed 2020-02-25 | $40.21M derived: sum of 2 quarters · filed 2020-02-25 | $54.47M derived: sum of 3 quarters · filed 2020-02-25 | $71.43M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2017-12-31 | $22.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $36.45M derived: sum of 2 quarters · filed 2020-02-25 | $53.40M derived: sum of 3 quarters · filed 2020-02-25 | $62.76M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $14.26M 10-Q · filed 2018-11-06 | $31.21M derived: sum of 2 quarters · filed 2018-11-06 | $40.57M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $16.95M 10-Q · filed 2018-08-06 | $26.31M 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $9.36M 10-Q · filed 2018-05-08 | ||||
| 2016-12-31 | $54.38M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |